ABSTRACT
INTRODUCTION
The incidence of subcutaneous or cutaneous metastasis from a visceral malignancy, excluding malignant melanoma, lymphoma, and leukemia, is rare. The reported incidence of subcutaneous metastasis is 5.3% and cutaneous metastasis accounts for 0.7% and 9% of all metastases (1).
Among all internal malignancies the reported the incidence of cutaneous metastasis in breast cancer is highest whereas in gall bladder cancer (GB Ca) is extremely rare (1). The most common metastatic sites for gall bladder cancer are the local lymph nodes, liver or surrounding peritoneal structures. Occasionally, extra-peritoneal metastases may occur, but these are primarily in the lungs and the pleura (2) . Metastases to distant subcutaneous tissue are exceedingly rare with only six reported cases of GB Ca with metastases to subcutaneous tissue (3). Primary breast cancer cells metastasize through the blood vessels to various distant organs, commonly, to the lung, liver and bones (4) . It has been reported that metastatic cutaneous lesions are seen more common in breast cancer than in any other malignancy in women, exceeding 20% of all cutaneous metastases (5).
Cateneous metastases indicate tumor infiltration of skin through blood capillaries, and lymph vessels. The presence of cutaneous metastasis signifies widespread systemic disease and a poor prognosis with reduced survival. Detection of cutaneous metastasis is important for staging of the disease and prognostication. The utility of PET-CT scan in identifying and evaluating cutaneous or subcutaneous metastases have been previously described in several studies (6-10). Here we have reported two cases of cutaneous metastases from gall bladder cancer and breast cancer, which were identified as hepermetabolic lesions during 18 FDG-PET-CT whole body scan for restaging of the disease. 9.0 X 8.0 mm size at 5 mm depth from skin surface was identified in high resolution 2D ultrasonography. Fine needle aspiration cytology from the swelling was done and showed metastatic adenocarcinoma, morphologically consistent with ductal carcinoma breast. She was subjected to whole body 18 FFDG PET-CT scan to restage the disease at a private PET centre, Dhaka. No abnormal FDG uptake was noted over the right chest wall and both axillae. Mild FDG uptake (SUV max 3.8) is noted in the swelling (1.5 cm X 1.2 cm) in the cutaneous layer at right buttok ( Figure  2 ). Finally the swelling was removed and metastatic deposit was confirmed by cyto-pathology. 
CASE ONE

DISCUSSION
Several studies have previously been reported about subcutaneous metastasis in patients with breast cancer, genitourinary cancers, colon cancers, gastric cancers, hepatocellular carcinomas, gynecologic cancers, esophageal, thyroid cancers, and lung cancers (11) . Subcutaneous metastases are quite common in patients with malignant melanoma of skin. In this uncommon report, subcutaneous metastasis from gall bladder cancer showed intense FDG avid lesion in PET-CT scan, which was hyper dense on CT scan. The lesion was located in adnominal wall at epigastria region. Similarly Sean F. Heavey et al reported a case of gall bladder carcinoma with multiple subcutaneous metastases located in different sites including anterior abdominal wall, which were FDG avid (3) on PET CT scan. Asymptomatic and wide spread subcutaneous metastases from breast cancer were detected as FDG avid subcutaneous lesion on PET-CT scan similar to the reported case two of breast cancer (11, 12) . Another study by Nghi C Nguyen et al on prevalence and nature of soft tissue metastases detected on PET-CT FDG showed FDG avidity in most of the subcutaneous metastases from melanoma, lymphoma, lung cancer and esophageal cancers and 49 % lesions were less than one centimeter in size. The lesions were hyper dense on CT scan similar to these presented cases (13) . Cutaneous breast metastases most commonly present on the chest wall. The abdomen, back, head and neck, scalp, and upper extremities also are common sites however the presented breast cancer has cutaneous metastasis in the gluteal region.
CONCLUSION
PET-CT imaging can reliably identify hypermetabolic cutaneous and subcutaneous metastases from FDG avid primary malignancies. PET-CT can help in accurately localize the lesion and provide accessible biopsy site thereby unnecessary invasive procedures could be avoided. Detection of FDG avid subcutaneous metastasis has prognostic implication and imaging can help not only to restage the disease but also to guide new therapeutic strategies.
